Tsutomu Takeuchi

Jun 1, 2024 | jrheum.org | Tsutomu Takeuchi |Naoko Wakasugi |Tetsuji Hashida |Satoshi Uno

Key Indexing Terms: immunosuppressive agent lupus nephritis postmarketing product surveillance Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease, predominantly affecting women of reproductive age.1,2 Asian populations are also disproportionately affected,1-3 with a reported prevalence of SLE in Japan of up to 38 per 100,000.3 SLE has a heterogeneous presentation, with clinical manifestations ranging from skin rashes to major organ involvement.1 Lupus nephritis...

May 28, 2024 | nature.com | Jun Inamo |Mahoko Takahashi Ueda |Hiroshi Nishida |Tsutomu Takeuchi |Kazuyoshi Ishigaki |Yasushi Ishihama

AbstractAlternative splicing events are a major causal mechanism for complex traits, but they have been understudied due to the limitation of short-read sequencing. Here, we generate a full-length isoform annotation of human immune cells from an individual by long-read sequencing for 29 cell subsets. This contains a number of unannotated transcripts and isoforms such as a read-through transcript of TOMM40-APOE in the Alzheimer’s disease locus.

Feb 9, 2024 | jrheum.org | Tsutomu Takeuchi |Naoko Wakasugi |Satoshi Uno |Tetsuji Hashida

Long-term safety and effectiveness of tacrolimus in patients with lupus nephritis in Japan: 10-year analysis of the real-world TRUST study Tsutomu Takeuchi, Naoko Wakasugi, Tetsuji Hashida, Satoshi Uno, Hirofumi Makino The Journal of Rheumatology Feb 2024, jrheum.2023-0210; DOI: 10.3899/jrheum.2023-0210

Nov 1, 2023 | accp1.onlinelibrary.wiley.com | Tsutomu Takeuchi |Taisho Pharmaceutical Co |Ltd. Osaka Japan |Yukihiro Chino

Ozoralizumab is a bispecific NANOBODY® compound that binds tumor necrosis factor alpha (TNFα) and human serum albumin (HSA). Ozoralizumab inhibits the TNFα physiological activity while maintaining long-term plasma retention owing to its HSA-binding ability. A population pharmacokinetic (PK) model was developed using data from 494 Japanese patients with rheumatoid arthritis (RA) in phase II/III and phase III trials to assess the effects of potential PK covariates.

May 17, 2023 | onlinelibrary.wiley.com | Yoshiya Tanaka |Tsutomu Takeuchi |Stephen Hall |Derek Haaland

ORIGINAL ARTICLE Yoshiya Tanaka and Tsutomu Takeuchi are co-first authors. Abstract Aim Certolizumab pegol (CZP), an Fc-free, PEGylated tumor necrosis factor inhibitor (TNFi), has shown rapid and sustained reduction in signs and symptoms of rheumatoid arthritis (RA). Elevated rheumatoid factor (RF) level has been associated with RA disease progression and poorer TNFi response. We assessed the efficacy of CZP in patients with early and established RA across baseline RF levels.